Higher Baxter sales boost Q4 earnings; Roche's Avastin wins extended colorectal cancer use;

@FiercePharma: Results from Slovenia's Krka show why pharma's so interested in emerging markets. E. European growth push sales up 6%. More | Follow @FiercePharma

 @AlisonBFierce: After a year-long voluntary moratorium, researchers are set to resume lab-bred bird flu studies. News | Follow @AlisonBFierce

> Baxter International ($BAX) posted an increase in quarterly earnings on stronger sales, particularly in the U.S. Report

> Roche's ($RHHBY) Avastin won FDA approval for a new use in colorectal cancer patients, in combination with a different chemotherapy regimen to be used after previous Avastin-plus-chemotherapy treatment has failed. Report

> Flush with a new supply contract, South Africa's Cipla Medpro is likely to ask for a higher buyout bid from India's drugmaker Cipla. Report

> Slovenia's Krka saw full-year sales rise 6%, thanks to growth in its eastern European sales, which offset declines in its home country. Report

> India's Lupin won FDA approval for its version of Teva Pharmaceutical's ($TEVA) Plan B contraceptive. Report

> Pfizer's ($PFE) antidepressant Pristiq, a follow-up to its Effexor blockbuster, beat placebo in an 8-week phase IV study; its side effects were "consistent" with previous research, the company said. Report

Medical Device News

 @FierceMedDev: FDA slaps Class I tag on Bausch + Lomb's eye surgery recall. Report | Follow @FierceMedDev

 @DamianFierce: Some companies are passing the cost of the device tax down to customers, and hospitals are none too pleased. Story | Follow @DamianFierce

> AngioDynamics spends $15M on microwave ablation tech. Article

> Recall charges drag down Stryker's strong Q4 sales. Story

Biotech News

 @FierceBiotech: Biogen bolsters MS biz with PhIII win for longer-lasting Avonex. News | Follow @FierceBiotech

@JohnCFierce: Flu researchers are getting back to work on controversial genetically engineered viruses, whether US likes it or not. More | Follow @JohnCFierce

@RyanMFierce: Merck CEO pledges to persist with 'good' cholesterol drug program. Story | Follow @RyanMFierce

> Bristol-Myers finds silver (tax) lining after Hep C disaster. News

> Baxter snags hemophilia candidate in $185M deal with Ipsen and broke biotech. Article

Vaccines News

> U.N. excludes vaccine preservative from mercury treaty. More

> Researchers set to resume lab-bred bird flu studies. Report

> Heightened flu season turns focus on vaccine advancements. Story

> Evidence mounts for GSK flu vaccine link to narcolepsy. News

> Novartis lands EU approval of meningitis B vaccine Bexsero. Article

Pharma Manufacturing News

> AmerisourceBergen seeing shifts in drug distribution business. Item

> Drug plants popping up in Kazakhstan. Story

> Counterfeit drug seizures fell significantly in 2012. Report

> Ben Venue consent decree softened to account for drug shortages. News

And Finally... Business leaders in Davos confront the obesity conundrum. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.